In a 52-week, randomized, double-blind, placebo-controlled clinical study, 96 patients between the ages of 5 and 31 years received Elaprase 0.5 mg/ kg every week (n=32) or 0.5 mg/ kg every other week (n=32), or placebo (n=32).